Achieving such a safety profile treating brain cancer is exceptional but totally ignored by the market. Yesterday there was an article about Pfizer's RSV vaccine which got a recommendation for FDA approval with a lot of safety concerns.
Pfizer's RSV vaccine one step closer to approval after narrowly receiving backing from FDA panel - ABC News
Just shows how important safety is and that even the big guys often struggle with that but strangely at Hopper's companies that gets totally ignored.
One day, the market will wake up.
GLTA
Ann: Fourth dose cohort initiated in CHM 1101 Phase 1 trial, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $28.14K | 7.037M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 243067 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 14771167 | 22 |
View Market Depth
| Last trade - 15.39pm 20/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |